Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

You may be eligible if

• Diagnosis of 1 of the following:
• * Acute myeloid leukemia
• * Myelodysplastic syndromes, including 1 of the following:
• * Refractory anemia with excess blasts (RAEB)
• * RAEB in transformation
• * Chronic myelomonocytic leukemia in transformation with ≥ 10% peripheral blood or bone marrow blasts
• * Acute lymphoblastic leukemia
• * Chronic myelogenous leukemia in blastic phase
• Relapsed or refractory disease, defined as 1 of the following:
• * Failed to achieve a complete response (CR) to a standard induction regimen
• * Relapsed after achieving a CR
• Failed last cytotoxic regimen before study entry
• No alternate, potentially curative option available
• No known CNS disease
• Performance status - ECOG 0-2
• SGOT and SGPT normal
• Bilirubin normal
• Creatinine normal
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV-positive patients with normal CD4 count and without AIDS-defining disease allowed
• No history of allergic reaction attributed to compounds of similar chemical or biologic composition to rebeccamycin analogue (XL119)
• No concurrent uncontrolled illness
• No active or ongoing infection
• No psychiatric illness or social situation that would preclude study compliance
• No prior allogeneic stem cell transplantation
• No concurrent prophylactic hematopoietic colony-stimulating factors (CSF)
• No epoetin alfa or hematopoietic CSF during course 1 of study therapy
• More than 7 days since prior cytotoxic chemotherapy except for hydroxyurea
• More than 7 days since prior radiotherapy
• Recovered from all prior therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent anticancer agents or therapies
• No other concurrent antileukemic agents or therapies
• No other concurrent investigational agents or therapies
• No other concurrent cytotoxic agents